Tiny Halo Therapeutics has rounded up $1.1 million from a dozen nonprofits to help set up a mid-stage study of its experimental drug for Duchenne muscular dystrophy. Halo, which has received all of its support so far from a pair of DMD patient groups, wants to launch a Phase II for HT-100, an oral drug designed to reduce fibrosis and promote healthy muscle fiber regeneration in DMD patients, in the second half of this year. Release